Astrazeneca Ab

Bo Peng

Daniel T Robbins

Michelle Lamb

Dedong Wu

Alexander Hird

Jeffrey Wallace Johannes

Wenzhan Yang

Steven Kazmirski

Xiaolan Zheng

Qing Ye

Matthew Belmonte

Paul Secrist

Stephanos Ioannidis

Bin Wang

Bin Yang

Tao Wang

Huiping Guan

Jamal Carlos Saeh

Mei Su

John Paul Secrist

Ying Kan

Hai-Jun Zhang

Brian Aquila

Timothy Pontz

Ying Kang

Victor Kamhi

Kumar Thakur

Xiaomei Feng

Daniel William Robbins

Lynsie Almeida

Steven Lee Kazmirski

Michelle Laurae Lamb

Matthew Alan Belmonte

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

Mcl-1 inhibitors and methods of use thereof

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10,000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

MCL-1 inhibitors and methods of use thereof

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.

Chemical compounds

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer. 

4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Growing community of inventors

Waltham, MA, United States of America

Bo Peng